http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yoon, Dok Hyun,Shin, Jae-Sik,Jin, Dong-Hoon,Hong, Seung-Woo,Jung, Kyung A,Kim, Seung-Mi,Hong, Yong Sang,Kim, Kyu-Pyo,Lee, Jae-Lyun,Suh, Cheolwon,Lee, Jung Shin,Kim, Tae Won Potamitis Press 2012 Anticancer research Vol.32 No.5
<P>Survivin is a negative regulator of apoptosis. We evaluated the efficacy of YM155, a selective suppressant of survivin, in combination with gemcitabine in the pancreatic cancer cell line MiaPaCa-2.</P>
Sorafenib for recurrent hepatocellular carcinoma after Liver transplantation
( Hyun Yoon Dok ),( Baek Yeol Ryoo ),( Min Hee Ryu ),( Sung Gyu Lee ),( Shin Hwang ),( Dong Jin Suh ),( Han Chu Lee ),( Jae Lyun Lee ),( Tae Won Kim ),( Heung Moon Chang ),( Chul Soo Ahn ),( Ki Hun Ki 대한내과학회 2009 대한내과학회 추계학술발표논문집 Vol.2009 No.-
Dok Hyun Yoon(윤덕현),Yoojin Cho(조유진),Ji Youn Kim(김지연),Sang Yoon Kim(김상윤),Soon Yuhl Nam(남순열),Seung-Ho Choi(최승호),Jong-Lyel Roh(노종렬),Sang-Wook Lee(이상욱),Jeong Hyun Lee(이정현),Jae Seung Kim(김재승),Kyung-Ja Cho(조 대한두경부종양학회 2011 대한두경부 종양학회지 Vol.27 No.2
서 론 5-FU와 cisplatin 병용항암화학요법은 국소진행성 두경부편평상피암의 유도화학요법으로 널리 사용되고 있는 요법이다. 저자들은 5-FU 대신 경구제재인 S-1을 cisplatin과 병용하는 복합항암요법의 효과와 안전성에 대해 연구하였다. 대상 및 방법 저자들은 2007년 2월부터 2008년 12월까지 S1과 cisplatin의 복합유도화학요법을 시행받은 3/4기 구인두, 하인두, 후두, 구강 편평상피세포암 환자 52명의 치료결과를 후향적으로 분석하였다. 유도항암화학요법은 제 1일에 cisplatin(75 또는 60mg/m 2 ), 제1일부터 14일까지 S-1(40mg/m 2 )을 1일 2회, 21일 간격으로 투여하였고 가능한 경우에는 항암방사선동시요법 또는 수술을 뒤이어 시행하였다. 결 과 전체 52명 중 37명(71.2%)에서 부분반응을 보였으나 완전반응은 관찰되지 않았다. 2년 무진행생존율은 56.9%, 2년 전체생존율은 68.2%였다. 유도항암요법과 관련된 유해반응으로는 호중구감소증(71.2%) 및 빈혈(63.5%) 등과 같은 혈액학적 부작용이 가장 흔했다. 결 론 S-1과 cisplatin의 복합항암화학요법은 국소진행성 두경부편평상피암 환자를 대상으로 한 유도화학요법으로 적용이 가능한 것으로 판단된다.
( Ji Hyun Park ),( Dok Hyun Yoon ),( Shin Kim ),( Jin Sook Ryu ),( Sang Wook Lee ),( Chan Sik Park ),( Joo Ryung Huh ),( Cheol Won Suh ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Despite its predictive role is well established in several aggressive types of lymphomas, clinical utility of positron emission tomography-computed tomography (PET-CT) scans in marginal zone lymphoma (MZL) remains yet unclear. Hence, we investigated whether PET-CT scans might also predict clinical courses in patients with MZL who underwent induction chemotherapy, Methods: A total of 32 MZL patients who underwent induction chemotherapy with comparable baseline, interim, and post-treatment PET-CT scans were enrolled. The primary endpoint was to compare event-free survival (EFS) by achievement of metabolic complete response (mCR) in post-treatment PET-CT scans. The secondary endpoint was to determine whether mCR in interim PET-CT or early metabolic responder, who achieved mCR since interim PET-CT, could predict more favorable EFS Results: Compared with non-mCR group, 5-year EFS was signifi cantly superior in patients who achieved mCR in interim PET-CT scans (70.6% VS 13.1%, p=0.007) as well as in post-treatment PET-CT (55.0% VS 0.0%p =0.010). Moreover, early metabolic responder showed more favorable 5-year EFS to patients with delayed or never achievement of mCR (70.6% VS 22.5% VS 0%, p=0.011). In addition, patients with high SUV showed strong trends of inferior EFS and OS with marginal statistical signifi cance (p= 0.072, and p=0.101, respectively). Conclusions: Achievement of mCR in interim as well as post-treatment PET-CT seems to well predict more favorable EFS in patients with MZL after induction chemotherapy. Moreover, earlier achieved mCR since interim PET-CT might be an independent predictor of superior 5-year EFS in these patients.
장근두,Dok Hyun Yoon,Shin Kim,이대호,이상욱,허주령,서철원 대한혈액학회 2011 Blood Research Vol.46 No.2
Background :The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been established. We aimed to evaluate the impact of R-CHOP compared with CHOP in patients with DLBCL and to establish clinical predictors of better outcomes in these patients. Methods :We retrospectively identified 177 patients diagnosed with CD20-positive DLBCL and treated with CHOP (N=82) or R-CHOP (N=95). The response rate, event-free survival (EFS), and overall survival (OS) rates were compared between the 2 treatment groups. All patients were classified into primary extranodal lymphoma (PENL) or nodal lymphoma (NL) subgroups, and the clinical parameters of each subgroup were analyzed. Results :The overall response rate was higher in R-CHOP group (95% vs. 84%, P=0.07). The 3-year EFS rate was significantly higher in R-CHOP group (71% vs. 52%, P=0.013), but the OS rate was comparable between the 2 groups (79% vs. 69%, P=0.23). A significant survival benefit was seen with R-CHOP compared to CHOP therapy in NL patients (P=0.002 for EFS and 0.04 for OS). Multivariate analyses confirmed that R-CHOP therapy is an independent prognostic factor for EFS (hazard ratio of 0.32 [0.17-0.62], P=0.001) and OS (hazard ratio of 0.4 [0.18-0.87], P=0.02) in NL patients. Conclusion :Patients in the PENL group did not benefit from R-CHOP chemotherapy.
Incidence of Gastric Involvement In Nongastric Marginal Zone Lymphoma
( Shin Kyo Yoon ),( Hwoon Yong Jung ),( Shin Kim ),( Dok Hyun Yoon ),( Joo Ryung Huh ),( Cheol Won Suh ) 대한내과학회 2011 대한내과학회 추계학술발표논문집 Vol.2011 No.1
Background: There is an assertion that esophagogastroduodenoscopy (EGD) should be included in the routine diagnostic work-up of extra nodal marginal zone lymphoma (MZL) based on an observation that a significant proportion of patients presenting with nongastric MZL had gastric involvement as well. However, incidence of gastric involvement in nongastric MZL has not been investigated in Asia, where incidence of MZL is higher than Western countries. Aims: The present study was undertaken to assess the incidence of gastric involvement in nongastric marginal zone lymphoma. Methods: Between April 1993 and December 2010, 153 consecutive patients with nongastric MZL were treated in the Asan Medical Center, Seoul, Korea. We retrospectively analyzed the results of these patients. Results: We present our experience of 47 cases of EGD which comprised 30.7% of all 153 nongastric MZL patients. The median age at diagnosis was 51 years, and the overall male-to-female ratio was 0.72. One hundred patients (86.3%) initially presented with localized disease (defined by Ann Arbor stage I/II), 2 (1.3%), 15 (9.8%), 4 (2.6%) patients were stage IIIa, IVa, IVb, respectively. In 136 patients (88.9%), single site of extranodal involvement of lymphoma was identified. The most common primary site of nongastric MZL was ocular adnexa and orbit (48.4%), intestine (11.1%), lung (9.8%), nasal sinus (5.9%) in decreasing order of frequency. Of 153 nongastric MZL patients, 47 patients (30.7%) were underwent EGD for initial staging work-up, and no patient was found to have gastric involvement of lymphoma. The most common endoscopic and pathologic diagnosis of EGD was chronic superficial gastritis (16 patients, 34%) (Table 1). Summary: None of the 47 patients who had undergone EGD had gastric involvement of EGD. Our findings do not support routine EGD in patients with extranodal MZL. Table1. Endoscopic diagnosis whom underwent EGD for routine work-up of extra nodal MZL.